In locally advanced rectal cancer (LARC), KRAS mutations have been identified as a biomarker of poor response to neoadjuvant chemoradiation (CRT), with KRAS and TP53 double mutants exhibiting particularly low rates of response [10, 11, 12]. The gene discussed is KRAS; the disease is rectal cancer.